SCHEMBL4229530

SCHEMBL4229530

O=C(O)N1CCC(Nc2ncc(CO)cc2Cl)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 1/20 0.40
NOS2 P35228 1/20 0.40
MCHR1 Q99705 1/20 0.40
EPHX2 P34913 1/20 0.40
PAK1 Q13153 7/20 0.39
CNR1 P21554 4/20 0.38
SCN1A P35498 1/20 0.38
SCN8A Q9UQD0 1/20 0.38
ADORA3 P0DMS8 1/20 0.37
HTR2A P28223 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
SLC6A4 P31645 1/20 0.37
OPRK1 P41145 1/20 0.37
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TRPV1 Q8NER1 2/20 0.35
CNR2 P34972 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4218922 0.93 SCN1A (0.40) NOS1NOS2MCHR1EPHX2PAK1
SCHEMBL4221845 0.86 JAK3 (0.42) MCHR1EPHX2SCN1ASCN8A
SCHEMBL27696246 0.83 ALDH1A1 (0.49) NOS1NOS2CNR1ADORA1CNR2
SCHEMBL4218975 0.83 MCHR1 (0.40) NOS1NOS2MCHR1EPHX2PAK1
SCHEMBL27677723 0.82 KMT2A (0.42) MCHR1ADORA3ADORA2AADORA1MEN1
SCHEMBL27677658 0.80 PIK3CD (0.49) CNR1ADORA1CNR2NPC1ALDH1A1
SCHEMBL4227701 0.79 EGFR (0.38) PAK1
SCHEMBL4229356 0.77 HCAR3 (0.48) NOS1NOS2
SCHEMBL4227169 0.77 SCN1A (0.58) MCHR1SCN1ASCN8AOPRK1
SCHEMBL4222919 0.77 SCN1A (0.58) MCHR1SCN1ASCN8AOPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7557127-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2009-07-07 US disclosed
US-20090054464-A1 HDAC INHIBITOR ASTELLAS PHARMA INC. (JP) 2009-02-26 US disclosed
US-7465731-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2008-12-16 US disclosed
EP-1776357-A1 HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) Astellas Pharma Inc. (JP) 2007-04-25 EP disclosed
US-20060052599-A1 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2006-03-09 US disclosed
WO-2006016680-A1 HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) ASTELLAS PHARMA INC. (JP) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052599-A1 HDAC inhibitor HDAC1, HDAC2, HDAC11 NOS1 3471/4885NOS2 3761/4885MCHR1 997/4885
US-20090054464-A1 HDAC INHIBITOR HDAC1, HDAC2, HDAC8 NOS1 3647/4885NOS2 3815/4885MCHR1 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.